T1 Energy Take Steps to Bring Investment to G2_Austin Solar Cell Project
AUSTIN, Texas, May 15, 2025 (GLOBE NEWSWIRE) -- T1 Energy Inc. (NYSE: TE) ('T1,' 'T1 Energy,' or the 'Company') announced this morning that the Company has entered into a Heads of Agreement to pursue an investment in the planned G2_Austin 5 GW solar cell manufacturing facility. The non-binding agreement was signed this week at a ceremony in Riyadh hosted by the Saudi Ministry of Investment ('MISA') to commemorate the Trump administration's 'America First' program and the Kingdom's commitment to investing in critical U.S. energy infrastructure projects.
'We wish to extend our sincerest appreciation to the Saudi Ministry of Investment for hosting our delegation. We are honored to sign this landmark agreement which is intended to bring in strategic capital to support America's advanced manufacturing sector,' said Daniel Barcelo, T1's Chief Executive Officer and Chairman of the Board. 'The U.S. needs to establish a domestic solar manufacturing supply chain, and T1 is at the forefront of that mission with our world-class operating G1_Dallas facility and planned G2_Austin project. This agreement is a positive step towards an investment to accelerate our development plans and our strategy to become a U.S. solar energy leader built on domestic content and leading-edge technology.'
Representatives from T1 and our Saudi partner, Manaar Gulf Saudi Arabia Ltd., signed the agreement on May 13th at a ceremony in Riyadh welcoming a U.S. delegation from the Trump administration and U.S. industrial partners to the Kingdom. The event promoted Gulf Corporation Council investment in America to support the 'America First' agenda.
'T1 is grateful to be part of a larger conversation to reshore American manufacturing through cooperative efforts with our overseas industrial partners,' added Daniel Barcelo. 'With this agreement in place, our teams will be working to secure this capital and advance T1's mission to bring investment, jobs, and key supply chains to America. As this relationship develops, we are also pleased to examine complementary opportunities to invest in the Kingdom's solar manufacturing sector.'
About T1 Energy
T1 Energy Inc. (NYSE: TE) is an energy solutions provider building an integrated U.S. supply chain for solar and batteries. In December 2024, T1 completed a transformative transaction, positioning the Company as one of the leading solar manufacturing companies in the United States, with a complementary solar and battery storage strategy. Based in the United States with plans to expand its operations in America, the Company is also exploring value optimization opportunities across its portfolio of assets in Europe.
To learn more about T1, please visit www.T1energy.com and follow us on social media.
Investor contact:
Jeffrey SpittelEVP, Investor Relations and Corporate Developmentjeffrey.spittel@T1energy.comTel: +1 409 599 5706
Media contact:
Russell GoldEVP, Strategic Communicationsrussell.gold@T1energy.comTel: +1 214 616 9715
Cautionary Statement Concerning Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation with respect to: a potential investment in G2 Austin; the Company's ability to bring in strategic capital to support America's advanced manufacturing sector; the Company being at the forefront of the development of domestic solar manufacturing supply chains; the Company's development plans and strategy to become a U.S. solar energy leader built on domestic content and leading-edge technology; the investment by the Gulf Corporation Council in America to support the 'America First' agenda; T1's participation in the reshoring of American manufacturing; the Company's mission to bring investment, jobs and key supply chains to America; and any complementary opportunities that T1 may explore with respect to investments in the Kingdom's solar manufacturing sector. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual future events, results, or achievements to be materially different from the Company's expectations and projections expressed or implied by the forward-looking statements. Important factors include, but are not limited to, those discussed under the caption 'Risk Factors' in (i) T1's annual report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (the 'SEC') on March 31, 2025, as amended and supplemented by Amendment No. 1 on Form 10-K/A filed with the SEC on April 30, 2025, (ii) T1's post-effective Amendment No. 1 to the Registration Statement on Form S-3 filed with the SEC on January 4, 2024, and (iii) T1's Registration Statement on Form S-4 filed with the SEC on September 8, 2023 and subsequent amendments thereto filed on October 13, 2023, October 19, 2023 and October 31, 2023. All of the above referenced filings are available on the SEC's website at www.sec.gov. Forward-looking statements speak only as of the date of this press release and are based on information available to the Company as of the date of this press release, and the Company assumes no obligation to update such forward-looking statements, all of which are expressly qualified by the statements in this section, whether as a result of new information, future events or otherwise, except as required by law.
T1 intends to use its website as a channel of distribution to disclose information which may be of interest or material to investors and to communicate with investors and the public. Such disclosures will be included on T1's website in the 'Investor Relations' section. T1, and its CEO and Chairman of the Board, Daniel Barcelo, also intend to use certain social media channels, including, but not limited to, X, LinkedIn and Instagram, as means of communicating with the public and investors about T1, its progress, products, and other matters. While not all the information that T1 or Daniel Barcelo post to their respective digital platforms may be deemed to be of a material nature, some information may be. As a result, T1 encourages investors and others interested to review the information that it and Daniel Barcelo posts and to monitor such portions of T1's website and social media channels on a regular basis, in addition to following T1's press releases, SEC filings, and public conference calls and webcasts. The contents of T1's website and its and Daniel Barcelo's social media channels shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
FMC Corporation (FMC) Declares Quarterly Dividend; KeyBanc Raises PT Ahead of Upcoming Q2 Results
FMC Corporation (NYSE:FMC), a cheaply priced stock popular among hedge funds and offering upside potential, is included in our list of the . A person inspecting a lithium-ion battery that is being recycled. On July 14, 2025, KeyBanc increased its price target on FMC Corporation (NYSE:FMC) from $53 to $61, maintaining an 'Overweight' rating. For a stock that is trading at $43.21 as of the time of writing, representing a 41.17% upside, per the analyst. The analyst signals growing optimism around the company's growth potential. Meanwhile, two days later, FMC Corporation (NYSE:FMC)'s board declared a regular quarterly dividend of $0.58 per share, payable on October 16, 2025. Amid the volatile market environment, this points to the company's commitment to shareholder returns and operational resilience. With decades of experience in developing and producing lithium amides, lithium alkoxides, lithium metal hydrides, alkyllithiums, and aryllithiums, FMC Corporation (NYSE:FMC) has enabled the production of agricultural and pharmaceutical intermediates. It is included in our list of cheap lithium stocks. FMC Corporation (NYSE:FMC), a global agricultural sciences company, offers sustainable crop protection and precision agriculture solutions. It is included in our list of cheap lithium stocks. While we acknowledge the potential of FMC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Most Undervalued Cloud Stocks Under $10 According to Hedge Funds and 11 Best Mineral Stocks to Buy According to Hedge Funds. Disclosure: None.
Yahoo
24 minutes ago
- Yahoo
Centene Corporation (CNC) Cuts Outlook After $1.8B ACA Revenue Hit
We recently compiled a list of Centene Corporation tops our list for being one of the most undervalued stocks. Centene Corporation (NYSE:CNC) tops the list for being one of the cheap stocks to buy. It is a major U.S. managed care organization, serving over 1 in 15 Americans through government programs like Medicaid, Medicare, and ACA exchanges, with a focus on underinsured populations. In July 2025, the company withdrew its 2025 earnings guidance after uncovering challenges in the ACA Marketplace. New actuarial data from 22 of its 29 states showed slower-than-expected membership growth and higher morbidity, meaning enrollees are sicker and costlier than anticipated. As a result, the business revised its risk adjustment revenue down by $1.8 billion, which could impact earnings by $2.75 per share. In response, Centene Corporation (NYSE:CNC) is re-evaluating its 2026 ACA pricing to reflect rising claims and morbidity trends, particularly in states with the largest member base. The company is also emphasizing its operational improvements, streamlining its business, divesting non-core assets, and strengthening its Medicaid and Medicare services. 15 States with the Best Healthcare in the US This development echoes a broader industry trend, as competitors face similar volatility in the ACA exchanges. With enhanced federal subsidies set to expire in 2026, it will be a pivotal year, making pricing corrections and policy adaptations crucial. Centene Corporation (NYSE:CNC) remains focused on core government-backed offerings, investing in Medicare quality and expanding behavioral health, aiming for resilience amid uncertainty. While we acknowledge the potential of CNC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
2 Top Dividend Stocks to Buy Right Now and Hold Forever
Key Points Amgen can replenish its lineup thanks to a deep pipeline. AbbVie has a knack for getting around headwinds. Both drugmakers have strong dividend track records. 10 stocks we like better than Amgen › Over the long run, dividends can make a significant difference in your returns, whether you choose to reinvest the payouts or retain the cash for other purposes. However, many companies that offer dividends aren't exactly attractive to hold on to for a long time. Some have somewhat shaky underlying operations, and others are not inclined to regularly raise their dividends. Thankfully, some income stocks on the market don't have these issues, and their shares are worth holding on to forever. Let's consider two examples: Amgen (NASDAQ: AMGN) and AbbVie (NYSE: ABBV). 1. Amgen If you're an income-seeking investor, Amgen has several qualities that you'll appreciate. First, it's a leader in healthcare, a defensive industry. The demand for the medicines that the company develops -- some of which are lifesaving -- won't stop even during economic downturns, nor will physicians stop prescribing them. Amgen is well equipped to perform regardless of economic conditions. The drugmaker generates consistent revenue and earnings. Second, it continues to innovate. True, it has encountered clinical setbacks of late; its investigational weight management medicine, MariTide, didn't perform as well in mid-stage studies as expected. However, the company recently reported phase 3 results for bemarituzumab, a medicine it's developing for gastric cancer, the fifth leading cause of cancer death worldwide. This product now appears likely to secure regulatory approval and make a meaningful contribution to Amgen's results for a while. The company will continue to face competition and patent cliffs, but it's been able to perform well over the long run despite these challenges, thanks to its innovative abilities. Amgen can also rely on licensing deals and acquisitions to bolster its lineup and pipeline. In 2023, it acquired Horizon Therapeutics and its medicine for thyroid eye disease, Tepezza, for about $28 billion. Amgen has been able to push Tepezza's reach far beyond what the smaller Horizon would have been able to accomplish; it earned approval for the medicines in countries like Japan and Brazil, while pouring money into advertising and marketing efforts. Third, Amgen has a strong track record of dividend payments. The biotech initiated a payout in 2011, and since then, it's increased its dividends every single year. It currently offers a forward yield of 3.1%, considerably higher than the S&P 500's average of 1.3%. And the cash payout ratio of 46.5% appears reasonable, leaving ample room for further payout increases. Amgen's ability to develop novel lifesaving medicines, its consistent financial results, and its regular payout increases make it a top dividend stock to buy and hold for the long term. 2. AbbVie Although AbbVie has lagged behind the market over the past three years, this period highlights the company's resilient qualities. After losing patent exclusivity in January 2023 for Humira, an immunology medicine that was its best-selling drug and also the most lucrative in the industry's history, management predicted that the company would return to top-line growth in 2025. AbbVie resumed revenue growth last year, ahead of schedule. It's not rare for drugmakers to go through several years of declining revenue following a major patent cliff, nor is it necessarily a cause for concern. AbbVie's ability to bounce back as quickly as it did speaks volumes about the strength of its underlying business, its ability to navigate competition -- biosimilar and otherwise -- and its long-term prospects. True, the company encountered a significant setback when a seemingly promising candidate for schizophrenia called emraclidine, which it had gotten its hands on through an acquisition, failed mid-stage studies. AbbVie has faced similar problems before and has bounced back. The company had bet on a cancer medicine called Rova-T to be a significant growth driver post-Keytruda. However, this medicine failed in the clinic. Instead, AbbVie is now relying on Skyrizi and Rinvoq, two immunosuppressants, to drive top-line growth. These medicines have surpassed its own expectations, and they should continue to be significant contributors for years to come. The company has consistently found ways to overcome setbacks and challenges. Its financial results remain robust; the pipeline is deep; the balance sheet is strong. And its dividend track record is outstanding: AbbVie is a Dividend King, boasting 53 consecutive years of payout increases. Its forward yield now tops 3.4%, while the cash payout ratio of 61.8% is still reasonable. This is another dividend stock that you could safely include in a long-term portfolio. Should you invest $1,000 in Amgen right now? Before you buy stock in Amgen, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amgen wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Amgen. The Motley Fool has a disclosure policy. 2 Top Dividend Stocks to Buy Right Now and Hold Forever was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
